StockData
Integrated BioPharma Inc logo

Integrated BioPharma Inc (INBP) stock

INBPOTCPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.18+0.00 (0.00%)

Close on Oct 19, 2026Market cap $5.59MP/E –Yield –

Integrated BioPharma ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Integrated BioPharma's ebitda for the twelve months ending Jun 30, 2026 was -$2.41M, down 203.2% year over year. For fiscal 2026 it was -$2.41M, down 203.2% from the year before. The highest annual figure on record is $6.12M in fiscal 2021.

Annual ebitda

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$2.41M-203.2%
FY2025Jun 30, 2025$2.34M+319.0%
FY2024Jun 30, 2024$558.00K+18.5%
FY2023Jun 30, 2023$471.00K-84.7%
FY2022Jun 30, 2022$3.08M-49.7%
FY2021Jun 30, 2021$6.12M+71.4%
FY2020Jun 30, 2020$3.57M+18.0%
FY2019Jun 30, 2019$3.03M+48.1%
FY2018Jun 30, 2018$2.04M-43.0%
FY2017Jun 30, 2017$3.58M+45.2%
FY2016Jun 30, 2016$2.47M+84.2%
FY2015Jun 30, 2015$1.34M-23.2%
FY2014Jun 30, 2014$1.74M+13.0%
FY2013Jun 30, 2013$1.54M–
FY2012Jun 30, 2012-$147.00K–
FY2011Jun 30, 2011-$8.00K–

Quarterly ebitda

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026-$799.00K-221.1%
Q3 FY2026CQ1 2026Mar 31, 2026-$1.02M-224.3%
Q2 FY2026CQ4 2025Dec 31, 2025-$836.00K-393.3%
Q1 FY2026CQ3 2025Sep 30, 2025$240.00K-58.3%
Q4 FY2025CQ2 2025Jun 30, 2025$660.00K+38.4%
Q3 FY2025CQ1 2025Mar 31, 2025$818.00K+89.4%
Q2 FY2025CQ4 2024Dec 31, 2024$285.00K–
Q1 FY2025CQ3 2024Sep 30, 2024$575.00K+2400.0%
Q4 FY2024CQ2 2024Jun 30, 2024$477.00K+192.6%
Q3 FY2024CQ1 2024Mar 31, 2024$432.00K+232.3%
Q2 FY2024CQ4 2023Dec 31, 2023-$374.00K-723.3%
Q1 FY2024CQ3 2023Sep 30, 2023$23.00K-80.5%
Q4 FY2023CQ2 2023Jun 30, 2023$163.00K-69.1%
Q3 FY2023CQ1 2023Mar 31, 2023$130.00K-87.9%
Q2 FY2023CQ4 2022Dec 31, 2022$60.00K-92.6%
Q1 FY2023CQ3 2022Sep 30, 2022$118.00K-82.4%
Q4 FY2022CQ2 2022Jun 30, 2022$527.00K-62.2%
Q3 FY2022CQ1 2022Mar 31, 2022$1.08M-40.3%
Q2 FY2022CQ4 2021Dec 31, 2021$809.00K-39.2%
Q1 FY2022CQ3 2021Sep 30, 2021$670.00K-57.9%
Q4 FY2021CQ2 2021Jun 30, 2021$1.40M+102.0%
Q3 FY2021CQ1 2021Mar 31, 2021$1.80M+73.4%
Q2 FY2021CQ4 2020Dec 31, 2020$1.33M+4.5%
Q1 FY2021CQ3 2020Sep 30, 2020$1.59M+180.8%
Q4 FY2020CQ2 2020Jun 30, 2020$691.00K+4.5%
Q3 FY2020CQ1 2020Mar 31, 2020$1.04M-20.4%
Q2 FY2020CQ4 2019Dec 31, 2019$1.27M+126.7%
Q1 FY2020CQ3 2019Sep 30, 2019$567.00K+14.3%
Q4 FY2019CQ2 2019Jun 30, 2019$661.00K-6.8%
Q3 FY2019CQ1 2019Mar 31, 2019$1.31M+75.9%
Q2 FY2019CQ4 2018Dec 31, 2018$562.00K+100.7%
Q1 FY2019CQ3 2018Sep 30, 2018$496.00K+59.5%
Q4 FY2018CQ2 2018Jun 30, 2018$709.00K-23.4%
Q3 FY2018CQ1 2018Mar 31, 2018$742.00K+41.3%
Q2 FY2018CQ4 2017Dec 31, 2017$280.00K-58.5%
Q1 FY2018CQ3 2017Sep 30, 2017$311.00K-78.6%
Q4 FY2017CQ2 2017Jun 30, 2017$925.00K–
Q3 FY2017CQ1 2017Mar 31, 2017$525.00K–
Q2 FY2017CQ4 2016Dec 31, 2016$675.00K–
Q1 FY2017CQ3 2016Sep 30, 2016$1.46M–

More Integrated BioPharma figures

See a number that looks wrong?